# Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

> **NCT00975039** · PHASE2 · TERMINATED · sponsor: **Steba Biotech S.A.** · enrollment: 8 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** WST11

## Key facts

- **NCT ID:** NCT00975039
- **Lead sponsor:** Steba Biotech S.A.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2011-06
- **Final completion:** 2012-09
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Early end of enrolment with regards to difficulty met to enrol patients .
- **Last updated:** 2016-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00975039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00975039, "Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00975039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*